CA-SMARTFRAME
13.2.2024 15:15:33 CET | Business Wire | Press release
Truepic, provider of secure content transparency infrastructure, and SmartFrame Technologies, a leading UK-based tech provider that is redefining the digital image standard, have deployed the first secure image protection model that is set to redefine the landscape of authenticity and uncompromised security with provenance in the global sports photography space.
SmartFrame, with its innovative image-streaming technology, has made substantial strides in ensuring the integrity and ownership of media collections. Photos backed by Truepic's trusted certificate authority undergo a seamless and secure verification process that compliantly signs SmartFrame's visual media at scale. Every image is equipped with the Coalition for Content Provenance and Authenticity’s (C2PA) Content Credentials, marking sports brands’ assets as authentic and providing a trusted source of information for online viewers.
Recognizing the importance of ensuring transparency and authenticity online, multiple sports enterprises and brands, such as Six Nations Rugby, New Zealand Rugby, and Manchester City F.C. have embraced SmartFrame’s image-streaming distribution model, supported by Truepic’s certificate authority. These premier sports organizations are elevating global brand protection while simultaneously contributing to a safer and more reliable online image ecosystem within sports photography. Furthermore, by adopting secure image streaming and embedding C2PA Content Credentials, they are setting a benchmark for how digital images are originated, published, consumed, and monetized online. This strategic move aligns with the critical need for enhanced security in the contextual advertising market, projected to reach over $500 billion by 2030, which sports enterprises can take advantage of to help ensure their continued profitability.
“SmartFrame and Truepic’s partnership represents a significant leap forward in digital media integrity,” said Jeffrey McGregor, CEO of Truepic. “SmartFrame’s cutting edge image-streaming network paired with Truepic’s authenticity infrastructure introduces the most efficient way for commercial partners to assure the integrity and ownership of media collections. We are proud to partner with a forward-thinking organization like SmartFrame on industry leading content integrity products.”
"As a fellow member of the C2PA, it's clear that the need for trust, security, and transparency in online visual content is as critical to SmartFrame as it is to Truepic,” explains Rob Sewell, CEO of SmartFrame Technologies. “This shared vision forms the cornerstone of our partnership. By integrating Truepic's widely respected authentication technology into our secure image publishing network, we gain the capability to authenticate images swiftly and effectively, and to provide users with a seamless and trustworthy experience. This collaboration marks the next phase in our mission to provide the highest level of protection and transparency for online content, and we are excited to embark on this journey with a company as esteemed as Truepic."
About Truepic
Truepic provides authenticity infrastructure for the internet. The company’s transparency tools deliver verifiable information about the origin and editing history of digital content. Truepic is dedicated to advancing products and services that establish transparency in digital content, empowering viewers and users to identify authenticity and differentiate human from computer-generated. Recognized as one of TIME’s Best Inventions and Fast Company’s World Changing Ideas, consumers, businesses, creators, and publishers trust Truepic’s technologies to make informed decisions. For more information, visit truepic.com.
About SmartFrame Technologies
Founded in 2015, SmartFrame Technologies is a London-based technology provider whose image streaming platform redefines the standard for online image publishing. It unites sports brands and other content owners with publishers, advertisers, and online audiences, and ensures that images are delivered in the highest quality with maximum security, clear provenance, and detailed analytics. Furthermore, through its contextual ad tech component, brands can reach audiences with high-impact, contextually targeted, in-image advertising and sponsorship placements in a way that recognizes the interests of its viewers and simultaneously complies with global privacy regulations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213285238/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom